NuvOx was honored with the AZBIO Fast Lane Award for the company's many achievements in the last 18 months. The award committee noted the company's advancements in clinical trials for brain cancer and stroke, and continued development in pre-clinical stage indications such as heart attack.
top of page
Search
Recent Posts
See AllTucson, AZ, September 18th, 2023 NuvOx Therapeutics (“NuvOx”) announced that it has closed an oversubscribed convertible notes round, raising approximately $7M out of the originally planned $5M. In th
Tucson, AZ, August 28th, 2023 NuvOx Pharma announced publication of a research article, “Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme” in Cancer Research Communications
Tucson, AZ, August 4th, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, annou
bottom of page